OBJECTIVES: Existing studies usually do not measure the free vitamin D in pediatric patients with inflammatory bowel disease (IBD) and not consider the effect of inflammation on vitamin D levels. The aim of our study was to evaluate the concentrations of vitamin D-binding protein (VDBP), total and free 25-hydroxyvitamin-D (25(OH)D), and to correlate these values with the disease activity markers. METHODS: Newly diagnosed children with IBD and a group of healthy controls (HCs) were enrolled. VDBP and total and free 25(OH)D levels were measured by enzyme-linked immunosorbent assay and compared using the Student t test. In each patient with IBD, the activity scores of disease and the main inflammation markers were correlated to total and free 25(OH)D levels. C-reactive protein was also measured in the control group, and it was related to VDBP by a linear regression test for all the groups. RESULTS: Fifty-one consecutive children were enrolled: IBD = 33, HC = 18. Levels of total 25(OH)D were higher in HC than in patients with IBD (P = 0.01). The free/total 25(OH)D ratio was, however, higher in patients with IBD compared to HC (P < 0.001). Finally, levels of VDBP were lower in patients with IBD than in HC (P = 0.001). A significant direct correlation was found between the free/total 25(OH)D ratio and the activity index of disease (r: 0.17; P = 0.01). Moreover, in patients with IBD and controls we found a significant indirect correlation between VDBP and C-reactive protein (r: 0.12; P = 0.01). CONCLUSIONS: Inflammation inversely correlates to VDBP concentrations and patients with IBD, despite their deficiency in total 25(OH)D, have normal or even higher levels of free 25(OH)D.
OBJECTIVES: Existing studies usually do not measure the free vitamin D in pediatric patients with inflammatory bowel disease (IBD) and not consider the effect of inflammation on vitamin D levels. The aim of our study was to evaluate the concentrations of vitamin D-binding protein (VDBP), total and free 25-hydroxyvitamin-D (25(OH)D), and to correlate these values with the disease activity markers. METHODS: Newly diagnosed children with IBD and a group of healthy controls (HCs) were enrolled. VDBP and total and free 25(OH)D levels were measured by enzyme-linked immunosorbent assay and compared using the Student t test. In each patient with IBD, the activity scores of disease and the main inflammation markers were correlated to total and free 25(OH)D levels. C-reactive protein was also measured in the control group, and it was related to VDBP by a linear regression test for all the groups. RESULTS: Fifty-one consecutive children were enrolled: IBD = 33, HC = 18. Levels of total 25(OH)D were higher in HC than in patients with IBD (P = 0.01). The free/total 25(OH)D ratio was, however, higher in patients with IBD compared to HC (P < 0.001). Finally, levels of VDBP were lower in patients with IBD than in HC (P = 0.001). A significant direct correlation was found between the free/total 25(OH)D ratio and the activity index of disease (r: 0.17; P = 0.01). Moreover, in patients with IBD and controls we found a significant indirect correlation between VDBP and C-reactive protein (r: 0.12; P = 0.01). CONCLUSIONS:Inflammation inversely correlates to VDBP concentrations and patients with IBD, despite their deficiency in total 25(OH)D, have normal or even higher levels of free 25(OH)D.
Authors: Rene F Chun; Albert Shieh; Carter Gottlieb; Vahe Yacoubian; Jeffrey Wang; Martin Hewison; John S Adams Journal: Front Endocrinol (Lausanne) Date: 2019-10-24 Impact factor: 6.055
Authors: Karolina Śledzińska; Piotr Landowski; Michał A Żmijewski; Barbara Kamińska; Konrad Kowalski; Anna Liberek Journal: Nutrients Date: 2022-02-28 Impact factor: 5.717
Authors: Dylan N Clements; Gemma Bruce; John M Ryan; Ian G Handel; Ioannis L Oikonomidis; Adam G Gow; Helen Evans; Susan Campbell; Emma Hurst; Richard J Mellanby Journal: J Vet Intern Med Date: 2020-10-14 Impact factor: 3.333
Authors: Jessica Cusato; Lorenzo Bertani; Miriam Antonucci; Cristina Tomasello; Gian Paolo Caviglia; Simone Dibitetto; Alessandro Massano; Michela Mangia; Jacopo Mula; Linda Ceccarelli; Francesco Costa; Federico Zanzi; Marco Astegiano; Davide Giuseppe Ribaldone; Antonio D'Avolio Journal: Pharmaceuticals (Basel) Date: 2021-11-27